• Policy
• 'Symbenda' withdraws from Korean market 3 years after reimb.
• by Lee, Tak-Sun Oct 29, 2021 05:54am

• Company
• Qtern will be released in Korea after 4 years of approval
• by Eo, Yun-Ho Oct 29, 2021 05:53am

• Policy
• KDCA “will monitor development of oral COVID-19 treatments"
• by Lee, Hye-Kyung Oct 29, 2021 05:53am

• Policy
• The government needs to create a sovereign wealth fund
• by Lee, Jeong-Hwan Oct 29, 2021 05:53am

• Product
• PO treatment for COVID-19 "Molnupiravir" will be released
• by Whang, byung-woo Oct 29, 2021 05:53am

• Company
• Bayer’s ‘Nubeqa’ can be prescribed at general hospitals
• by Eo, Yun-Ho Oct 28, 2021 05:59am

• InterView
• Patients with severe diseases don't really like Mooncare
• by Lee, Jeong-Hwan Oct 28, 2021 05:59am

• Company
• “Prolia·Evenity drives the osteoporosis treatment market”
• by Oct 28, 2021 05:59am

• Company
• Samsung BioLogics' sales surpassed ₩1 trillion
• by Chon, Seung-Hyun Oct 28, 2021 05:58am

• Policy
• Multinational companies have more drugs for PVA
• by Lee, Hye-Kyung Oct 28, 2021 05:58am